Financial Performance - Q3 2025 - Revenues reached $41.4 million, a 25.5% increase compared to $33.0 million in Q3 2024, driven by drybulk fleet additions[5] - Operating income increased significantly to $10.3 million in Q3 2025, a roughly 72% increase ($4.3 million) compared to Q3 2024 and a 22.6% increase ($1.9 million) compared to Q2 2025[6] - EBITDA for Q3 2025 was $17.9 million, a 46.7% increase compared to $12.2 million in Q3 2024[6] - Net income for Q3 2025 was $11.0 million, compared to $10.0 million in Q3 2024[6] Financial Performance - 9M 2025 - Net income for 9M 2025 reached $35.0 million[6] - EBITDA for 9M 2025 was $49.7 million[6] - Operating cash flow generation for 9M 2025 was $57.0 million[6] Liquidity and Fleet - Cash and cash equivalents, including time deposits, amounted to approximately $100 million as of September 30, 2025, with a current cash base of about $172 million[6] - The company concluded a capital raise of $60 million through a registered direct equity offering, intended for further fleet growth[6] - Fleet operational utilization for Q3 2025 was 88.7%, compared to 65.6% in Q3 2024[6] - Approximately 75% of the total fleet calendar days were dedicated to time charter activity, while about 25% were dedicated to spot activity[4]

GENERATIVE AI DRUG CREATION ABS-201 KOL SEMINAR ABSCI CORPORATION 2025 ALL RIGHTS RESERVED Disclaimers Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predic ...

Financial Performance - Q4 FY2025 - Revenue for Q4 FY25 was $81.2 million, compared to $96.4 million in Q4 FY24[15] - EBITDA for Q4 FY25 was $6.6 million, compared to $10.7 million in Q4 FY24[15] - Free Cash Flow for Q4 FY25 was $10.7 million, compared to $12.2 million in Q4 FY24[15] Financial Performance - Full Year FY2025 - Revenue for FY25 was $344.5 million, compared to $395.9 million in FY24[18] - EBITDA for FY25 was $23.0 million, compared to $42.0 million in FY24[18] - Free Cash Flow for FY25 was $34.0 million, compared to $26.5 million in FY24[18] Debt and Capital Allocation - Total debt was reduced by $10.7 million in Q4 to $131.6 million[9, 20] - Mandatory term debt is paid through September 30, 2026, a year ahead of schedule[9, 22] Strategic Updates - DLH received CMMC Level 2 certification, positioning the company for high-value business in defense markets[9] - DLH was awarded an NIH Office of Information Technology contract[9]

Pedra Branca Royalty Acquisition - Gold Royalty Corp is set to acquire a royalty over the Pedra Branca mine in Brazil for $70 million in cash from BlackRock World Mining Trust plc[9, 39] - The royalty terms include a 25% net smelter royalty (NSR) on gold and a 2% NSR on copper[9, 39] - The royalty covers the Pedra Branca East and West deposits without step-downs or buybacks[9, 39] - The Pedra Branca East mine achieved first production in 2020 as a 1.0 million tonnes per annum (Mtpa) operation[9, 39] Financial Performance and Outlook - The royalty generated approximately $7.9 million in revenue for the 12 months ended June 30, 2025, equivalent to approximately 2,800 gold equivalent ounces (GEOs)[15, 39] - Gold Royalty is now debt-free with nearly $100 million in available cash and unused credit facilities[16] Asset Details - Pedra Branca is located in the Carajás region of Brazil's Pará state[9, 39] - Mineral resources at Pedra Branca are estimated at 26 million tonnes (Mt) at 0.41 g/t Au and 1.38% Cu[21] - The mine has proven reserves of 1.3 Mt at 0.48 g/t Au and 1.80% Cu, and probable reserves of 3 Mt at 0.49 g/t Au and 1.85% Cu[26] Ownership and Strategic Support - CoreX Holding BV agreed to acquire Pedra Branca from BHP on August 18, 2025[9, 39] - CoreX Holding is a global holding company operating across 10 industries, with a focus on metals and mining[35] - Strategic investors and insiders hold 10% of the company's shares, with institutional investors holding 10% and public and other investors holding 8%[37]

I N V E S T O R U P D A T E | D E C E M B E R 1 1 , 2 0 2 5 Agenda Welcome and Agenda Built to Win & Built to Last Lori Flees, President & Chief Executive Officer Operational Excellence Linne Fulcher, Chief Operating Officer Break Franchise Advantage & Growth Drivers Adam Worsham, Chief Franchising Officer Clear Roadmap to Accelerating Growth and Driving Performance Kevin Willis, Chief Financial Officer Q&A 2 Safe Harbor Forward-Looking Statements Certain statements herein, other than statements of historic ...

Strategic Goals - Weyerhaeuser aims to add $1.5 billion of incremental Adjusted EBITDA by 2030, measured against a 2024 baseline[11, 14] - The company targets a cash return to shareholders of 75-80% of Adjusted Funds Available for Distribution (Adjusted FAD) annually[14, 96] - The company has recycled ~$850 million of non-core Timberlands from 2022-2025[54] - The company has completed More Than $1.2B of High-Quality Acquisitions from 2022-2025[54] Business Performance & Growth Initiatives - Timberlands & Strategic Land Solutions generated ~$850 million to $1.2 billion Annual Adjusted EBITDA range over the last 8 years[39] - Wood Products generated ~$1.5 billion Annual Adjusted EBITDA 8-Year Average[41] - The company has identified $1 billion of line-of-sight growth initiatives by 2030[68] - For every $100 per MBF change in lumber prices, the company generates $500 million in annual Adjusted EBITDA[76] - The company has increased annual Adjusted EBITDA to $100 million from Climate Solutions in 2025[54] Market & Operational Advantages - Weyerhaeuser holds 10.4 million acres of timberlands in the U S and licenses 13 million acres in Canada[18] - The company's distribution business covers 70% of the new residential construction market[174] - The company captured $175 million in OpX Improvements Across Our Businesses from 2022-2025E[54]

Company Overview - Culp Inc is a major player in North America's mattress and upholstery fabrics market[6] - The company's fiscal year 2025 revenue was $213.2 million[7] - The bedding segment accounted for 53% of fiscal 2025 revenue, while the upholstery segment accounted for 47%[8] Liquidity and Financial Position - As of November 2, 2025, Culp had a total liquidity of $28.1 million, potentially increasing to $31.1 million with estimated proceeds from a Canadian real estate sale[16] - The company has U S Federal NOL carryforwards totaling approximately $88.1 million as of April 27, 2025[17] Restructuring and Cost Savings - Culp completed restructuring actions in fiscal year 2025 projected to yield $10 to $11 million in annualized cost savings and efficiency gains[21] - Additional integration actions in fiscal year 2026 are expected to generate approximately $8 million in total annualized additional benefits[32] - Total cost and efficiency actions are projected to save approximately $17.5 million annually, with pricing initiatives expected to add another $2.5 million, totaling approximately $20 million in combined savings and revenue gains[33] Market Conditions and Outlook - The company anticipates a potential recovery in the bedding market, with UBS forecasting 4% growth in 2026 and 8% growth in 2027[46] - Historical data suggests that bedding industry downturns since 1980 have never exceeded 4 years, followed by periods averaging 4% growth[54, 56]

Company Overview - AC Immune is focused on precision prevention of neurodegenerative diseases, particularly Alzheimer's and Parkinson's [4] - The company has potential partnering milestones exceeding CHF 4.3 billion [4] - As of September 30, 2025, AC Immune's cash reserves were CHF 108.5 million [6], equivalent to approximately USD 136 million [4] - The company has 100.9 million shares outstanding [6] ACI-7104 Phase 2 Interim Results - The Phase 2 study of ACI-7104 included a total enrollment of 34 patients [24] - The most common adverse events (AEs) were injection site reactions (55.9%), headaches (14.7%), and fatigue (11.8%) [28] - ACI-7104 demonstrated a 100% responder rate for anti-PD012 antibody titers in serum [29] - ACI-7104 treatment showed a trend towards stabilization of disease progression, with the MDS-UPDRS Part III total score suggesting stabilization [67] Biomarker and Imaging Findings - ACI-7104 immunization stabilized total alpha-synuclein levels in cerebrospinal fluid (CSF), demonstrating target engagement [41] - Neurofilament light chain (NfL) levels in CSF remained stable in the ACI-7104 group, suggesting a potential slowing of neurodegeneration [43] - Dopamine transporter (DaT-SPECT) imaging suggested stabilization of Parkinson's disease pathology [50]

Perimeter Solutions MMT Acquisition Call December 11, 2025 Disclaimer Certain statements in this presentation and discussion are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on Perimeter Solutions, Inc.'s (the "Company") expectations, intentions and projections regarding the Company's future performance, anticipated events or trends and other matters that are not historical facts. Words such as "anticipate," "estimate," "seek," "expect," ...

Ciena Corporation Fiscal Q4 2025 Earnings Presentation Period ended November 1, 2025 December 11, 2025 © Ciena Corporation 2025. ll rights reserved. Proprietary Information. Forward-looking statements and non-GAAP measures You are encouraged to review the Investors section of our website, where we routinely post press releases, Securities and Exchange Commission (SEC) filings, recent news, financial results, supplemental financial information, and other announcements. From time to time, we exclusively post ...